Dr. Moira Gilchrist
      OUR PEOPLE

      Dr. Moira Gilchrist

      PhD in Pharmaceutical Sciences, BSc in Pharmacy

      Chief Communications Officer

      Contact

      Dr. Moira Gilchrist became Chief Communications Officer at Philip Morris International (PMI) in January 2024. In this role, she leads PMI’s efforts to communicate its transformation into a smoke-free business and engages with the public on topics related to smoke-free alternatives and their scientific substantiation.​

      She was previously Vice President Strategic and Scientific Communications, a role she assumed in 2018, and held several positions within PMI, including leading the Reduced-Risk Products* Corporate Affairs team, serving as Director of Scientific Engagement within the research and development (R&D) function, and working in both product development and commercialization.​

      She holds a degree in Pharmacy and a PhD in Pharmaceutical Sciences, both from the University of Strathclyde in Glasgow, Scotland.​

      Before joining PMI in 2006, Moira worked in the pharmaceutical sector for more than a decade. She was a principal consultant within PwC's and IBM's pharmaceutical industry consulting groups and held positions within both industry and nonprofit organizations as a developer of drug formulations.​

       

      *Reduced-Risk Products is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking.​

      Latest Publications

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.